Freestone Grove Partners LP CVS — CVS HEALTH CORP

Ownership history in Freestone Grove Partners LP  ·  5 quarters on record

AI Ownership Summary

Freestone Grove Partners LP reported CVS HEALTH CORP (CVS) in 5 quarterly 13F filings from 2024 Q4 through 2025 Q4. Peak portfolio weight reached 0.7% in 2025 Q3. The latest visible filing shows CVS at 0.64% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this CVS ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Freestone Grove Partners LP's position in CVS HEALTH CORP, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

CVS was reported at 0.64% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.7% in 2025 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q4 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

CVS stock page Freestone Grove Partners LP fund profile Freestone Grove Partners LP full holdings
How Freestone Grove Partners LP held CVS — position size vs. price
% of Fund (quarterly)    CVS price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 REDUCED 10.8% -8.8% ✅ 1,112,239 -134,083 -10.8% 0.64% $88.3M 2026-02-14 (Est.) $77.80
2025 Q3 REDUCED — — — 1,246,322 -1,216 -0.1% 0.70% $94.0M 2025-11-14 $76.50
2025 Q2 ADDED — — — 1,247,538 +284,342 +29.5% 0.65% $86.1M 2025-08-14 $65.08
2025 Q1 ADDED — — — 963,196 +156,621 +19.4% 0.67% $65.3M 2025-05-15 $58.34
2024 Q4 INITIATED — — — 806,575 — — 0.44% $36.2M 2025-02-14 $62.86

🏢 Other funds also holding CVS

As of 2026 Q1 — sorted by position size

Employees Provident Fund Board 4.31% DAVIS SELECTED ADVISERS 3Y 7Y 4.04% Alexander Randolph Advisory, Inc. 3.58% PZENA INVESTMENT MANAGEMENT LLC 3Y 7Y 3.21% Permit Capital, LLC 3Y 7Y 3.06% Polaris Capital Management, LLC 3Y 7Y 3.04% Value Partners Investments Inc. 3Y 2.96% Hamlin Capital Management, LLC 3Y 7Y 2.85% SECTOR GAMMA AS 3Y 7Y 2.3% Stolper Co 3Y 2.28%

FAQ About Freestone Grove Partners LP and CVS

These are the practical questions this page is built to answer before you even open the full history table.

How long has Freestone Grove Partners LP reported owning CVS?

Freestone Grove Partners LP reported CVS across 5 quarterly 13F filings, from 2024 Q4 through 2025 Q4.

What was the largest reported CVS position in Freestone Grove Partners LP's portfolio?

The largest reported portfolio weight for CVS was 0.70% in 2025 Q3.

What is the latest reported CVS position on this page?

The most recent filing on this page is 2025 Q4, when Freestone Grove Partners LP reported 1,112,239 shares, equal to 0.64% of portfolio, with an estimated market value of $88.3M.

What does the chart on this CVS ownership page compare?

The chart compares Freestone Grove Partners LP's quarterly CVS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Freestone Grove Partners LP time their CVS position?

Based on 13F filing dates vs. subsequent CVS price moves, Freestone Grove Partners LP correctly timed 2 out of 4 reported position changes (50%). The annualised alpha on CVS relative to SPY over the holding period was +9.4%.

← Back to Freestone Grove Partners LP Holdings